Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening

Rhea-AI Summary

Guardant Health (Nasdaq: GH) will present data from 16 studies at the 2024 ASCO Annual Meeting, May 31-June 4 in Chicago. The studies highlight the impact of Guardant's blood tests and real-world data on precision oncology and cancer screening. Key presentations include interim data from the RADIOHEAD study showing correlations between epigenomic biomarkers and immunotherapy responses across 13 cancer types.

Presentations will cover the utility of ctDNA for therapy response monitoring, the use of the GuardantINFORM clinical-genomic database to study tumor drivers and resistance, and applications of genomic and epigenomic biomarkers in cancer treatment. Featured studies focus on racial differences in genomic profiles in metastatic breast cancer and the quantification of tumor fractions using the Guardant Infinity platform.

Positive

• Presenting 16 studies at ASCO 2024 highlights Guardant Health's active role in cancer research.
• Interim data from the RADIOHEAD study shows promising correlations between epigenomic biomarkers and immunotherapy responses.
• The use of Guardant Infinity and GuardantINFORM platforms for advanced cancer analysis and treatment monitoring demonstrates technological innovation.
• Studies focus on important clinical outcomes like therapy response monitoring and identifying resistance mechanisms.
• Guardant's inclusion of racial differences in genomic profiling addresses critical health disparities.

Negative

• No final data presented, only interim results, which may not fully reflect long-term outcomes.
• Many studies still in early phases, indicating potential delays before clinical application.
• No direct financial data or revenue impact mentioned, leaving questions about immediate business effects.

• Studies demonstrate benefits of liquid biopsy and real-world data in targeted therapy selection and therapeutic outcomes in advanced breast cancer
• Interim data from PICI’s RADIOHEAD study using Guardant Infinity™ platform show correlation between epigenomic biomarkers and patient response to immunotherapy treatment across more than 13 cancer types

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from 16 studies highlighting the role of Guardant blood tests and real-world data in advancing precision oncology and cancer screening at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, May 31-June 4 in Chicago.

Featured presentations will share data supporting the utility of therapy response monitoring with circulating tumor DNA (ctDNA) using Guardant Infinity and the use of the GuardantINFORM™ clinical-genomic database to characterize drivers and resistance mechanisms and their association with real-world outcomes in a variety of solid tumor types. Additional studies will present data supporting the application of genomic and epigenomic biomarkers in areas such as minimal residual disease detection and cohort characterization.

“The robust data we present at ASCO will further demonstrate the important scientific and clinical developments in cancer care that are possible using liquid biopsy,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Several studies will highlight the tremendous potential of epigenomic analysis using our Guardant Infinity platform to quantify tumor fraction and characterize therapy resistance mechanisms in order to improve treatment response across multiple cancer types.”

Featured presentations include:

• An oral presentation of a study using the Guardant360® liquid biopsy and exploring racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer (Abstract 1017, Monday, June 3, 11:30 am – 1:00 pm, Hall D1)
• Interim data readout from the collaboration between Guardant Health and the Parker Institute for Cancer Immunotherapy (PICI) to identify genomic and epigenomic biomarkers using Guardant Infinity for quantification of tumor fraction and association with outcomes from the RADIOHEAD real-world advanced pan-cancer cohort (Abstract 2570, Saturday, June 1, 9:00 am – 12:00 pm, Hall A)

Complete list of Guardant Health and collaborator presentations at ASCO

Abstract

Title (Hall A unless otherwise noted)

Product

Saturday, June 1 | 9:00 am – 12:00 pm

2570		Use of a tissue-free epigenomic circulating tumor DNA (ctDNA) assay for quantification of tumor fraction (TF) and association with outcomes from RADIOHEAD real-world advanced pan-cancer cohort		Guardant Infinity
3041		Association of KRAS G12D vs. G12V circulating tumor DNA variant allele fraction and real-world overall survival in metastatic non-small cell lung and colorectal cancers		Guardant Infinity

Saturday, June 1 | 1:30 pm – 4:30 pm

LBA3557		A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating tumor DNA (ctDNA): TACT-D		Guardant360 CDx
3519		Candidate molecular alterations associated with potential resistance in KRAS G12D gastrointestinal cancers		Guardant360 & Guardant360/CDx
3602		Characteristics of patients (pts) with disease relapse despite absence of molecular residual disease (MRD) after resection of colorectal oligometastases (CRM): implications from PRECISION study		Guardant360 & Guardant Reveal™
3545		Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort		GuardantINFORM

Sunday, June 2 | 9:00 am – 12:00 pm

1037		Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC)		Guardant Infinity
1043		Evaluating metrics of circulating tumor DNA response and progression using a high sensitivity tumor-agnostic assay in metastatic HR+/HER2- breast cancer receiving endocrine therapy and a CDK4/6-inhibitor		Guardant Infinity
1071		Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC)		GuardantINFORM
5069		Dynamic androgen receptor alterations (ARa) ctDNA profiles and clinical outcomes in metastatic prostate cancer (mPC)		GuardantINFORM

Monday, June 3 | 9:00 am – 12:00 pm | Hall A

5592

Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC)

Guardant Infinity

Monday, June 3 | 11:30 am – 1:00 pm | Hall D1

1017

Rapid Oral Abstract Session: Racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer

Guardant360

Online only

e13097		Co-occurrence of ESR1 and PIK3CA mutations in HR+/HER2- metastatic breast cancer: Incidence and outcomes with targeted therapy		Guardant360 & Guardant360 CDx
e12566		Molecular profiling in ABC: Is complementary testing with tissue and plasma necessary and clinically relevant?		Guardant360
e13702		Utilization of circulating tumor DNA (ctDNA) testing by race and ethnicity in more than 135,000 patients		GuardantINFORM
e20088		Use of cell-free tumor DNA in early detection of lung cancer		Shield™ (next generation)

The full abstracts for Guardant Health and a list of all abstracts being presented at the meeting can be found at the ASCO website.

For more information and updates from the meeting, follow Guardant Health on LinkedIn and X (Twitter) or visit ASCO booth #28115.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240530753528/en/

Investor Contact:

Zarak Khurshid

investors@guardanthealth.com

Media Contact:

Michael Weist

press@guardanthealth.com

+1 317-371-0035

Source: Guardant Health, Inc.

FAQ

What is Guardant Health presenting at the 2024 ASCO Annual Meeting?

Guardant Health will present data from 16 studies focusing on precision oncology and cancer screening, including the use of liquid biopsy and real-world data.

What are the key findings from Guardant Health's RADIOHEAD study?

Interim data from the RADIOHEAD study show correlations between epigenomic biomarkers and patient responses to immunotherapy across over 13 cancer types.

How does Guardant Health utilize ctDNA in cancer treatment?

Guardant Health uses ctDNA for therapy response monitoring and to study tumor drivers and resistance mechanisms.

What is the significance of the Guardant Infinity platform?

The Guardant Infinity platform is used to quantify tumor fractions and characterize therapy resistance mechanisms, helping improve cancer treatment responses.

Are there studies on racial differences in cancer treatment presented by Guardant Health?

Yes, one study using the Guardant360 liquid biopsy explores racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer.